Misonix Announces New Distribution Agreement for Brazil

Share this story with your network

FARMINGDALE, N.Y., Feb. 3 /PRNewswire-FirstCall/ — Misonix, Inc. (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, has entered into a new, three year distribution agreement with Neuro Orthopaedics Surgeries, based near Rio de Janeiro, Brazil, for the distribution of the SonaStar™ Ultrasonic Surgical Aspirator and the BoneScalpel™ Ultrasonic Bone Cutter. The agreement provides Neuro Orthopaedics Surgeries with the right to sell exclusively in Braziland includes minimum purchase requirements.  The addition of Neuro Orthopaedics Surgeries marks the Company’s 8th distributor in Latin America, which is part of an organization of over 30 export distributors worldwide.

Neuro Orthopaedics Surgeries is widely recognized for their success in introducing state-of-the-art medical devices and capital equipment to the Brazilian surgical marketplace.  In particular, their special expertise in neuro and spine surgery is well known.

The SonaStar is used by Neuro and General Surgeons for quick and efficient removal of both hard and soft tumors while sparing most vessels.  In addition, OsteoSculpt™ bone sculpting technology can be employed with the SonaStar to safely remove osseous structures, thus providing access to the surgical site.

The BoneScalpel is a tissue specific osteotomy device capable of making precise cuts through bone and hard tissue while largely preserving delicate soft tissue structures.  It offers the convenience and speed of a power instrument without the danger associated with rotary sharps.

“Misonix is pleased to add Neuro Orthopaedics Surgeries to our family of Latin American specialty distributors, a geographic area that is receiving a special emphasis from our Sales and Marketing team,” said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. “We are particularly pleased that they will be distributing two of our key products through their well established surgical products organization.”

About Misonix:

Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment.  Misonix’s therapeutic ultrasonic platform is the basis for several innovative medical technologies.  Addressing a combined market estimated to be in excess of $3 billion annually; Misonix’s proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications.  Additional information is available on the Company’s Web site at www.misonix.com.

With the exception of historical information contained in this press release, content herein may contain “forward looking statements” that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995.  These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances.  Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships,  regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company’s business lines, and other factors discussed in the Company’s Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.  The Company disclaims any obligation to update its forward-looking relationships.

Investor Relations Contact:
Cameron Associates, Inc.
212-245-4577
Kevin@cameronassoc.com

SOURCE Misonix, Inc.

RELATED LINKS
http://www.misonix.com

Leave a Comment

Your email address will not be published. Required fields are marked *

*